Clinically important interaction betweenmetoprolol and propafenone

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F13%3AE0103373" target="_blank" >RIV/00843989:_____/13:E0103373 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/61988987:17110/13:A14019WF

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Clinically important interaction betweenmetoprolol and propafenone

Popis výsledku v původním jazyce

A combination of antiarrhythmic drugs with ß1 selective blocking agents has often been used. Both these types of drugs are metabolized via the cytochrome P450 (CYP) enzyme system, and therefore potential drug interactions are of considerable clinical significance. The antiarrhythmic agent propafenone undergoes CYP 2D6?dependent metabolism. Propafenone is also an inhibitor of the enzyme; the inhibitory constant has been estimated at 50 nmol/L, similar to that of quinidine (60 nmol/L). Metoprolol, a ß1 selective blocking agent, undergoes extensive presystemic elimination by CYP 2D6, and it has been shown that metabolites do not substantially contribute to the ß1-blockade. Metoprolol has a dose-dependent effect; dose is commonly titrated to the highest dose tolerated in order to achieve the maximal effect in the absence of adverse effects. A 2- to 5-fold increase in steady-state levels of metoprolol has been described after adding propafenone to metoprolol therapy. The disposition of CYP

Název v anglickém jazyce

Clinically important interaction betweenmetoprolol and propafenone

Popis výsledku anglicky

A combination of antiarrhythmic drugs with ß1 selective blocking agents has often been used. Both these types of drugs are metabolized via the cytochrome P450 (CYP) enzyme system, and therefore potential drug interactions are of considerable clinical significance. The antiarrhythmic agent propafenone undergoes CYP 2D6?dependent metabolism. Propafenone is also an inhibitor of the enzyme; the inhibitory constant has been estimated at 50 nmol/L, similar to that of quinidine (60 nmol/L). Metoprolol, a ß1 selective blocking agent, undergoes extensive presystemic elimination by CYP 2D6, and it has been shown that metabolites do not substantially contribute to the ß1-blockade. Metoprolol has a dose-dependent effect; dose is commonly titrated to the highest dose tolerated in order to achieve the maximal effect in the absence of adverse effects. A 2- to 5-fold increase in steady-state levels of metoprolol has been described after adding propafenone to metoprolol therapy. The disposition of CYP

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FR - Farmakologie a lékárnická chemie

OECD FORD obor

—

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2013

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Canadian family physician

ISSN

0008-350X

e-ISSN

—

Svazek periodika

59

Číslo periodika v rámci svazku

n. 4

Stát vydavatele periodika

CA - Kanada

Počet stran výsledku

3

Strana od-do

"p. 373-375"

Kód UT WoS článku

000317812300014

EID výsledku v databázi Scopus

—